Ocugen develops gene therapies aimed at treating inherited retinal diseases and other conditions that cause vision loss. It last closed at $0.77 on Nov 20, up 4.79% on the day. The next earnings report for OCGN is expected around Wed, Mar 3, 2027, after the close. For the quarter ended Sep 2026, OCGN reported EPS of -$0.01 on revenue of $2.0M, with revenue up 11.4% from a year ago. Over its last 8 reports the stock moved an average of 7.4% the session after earnings. Over the last 12 months OCGN insiders bought $26K of stock on the open market and sold $1.1M, according to SEC Form 4 filings.
AI Auto Pilots
Is OCGN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold OCGN.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on OCGNStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
OCGN · as of the Nov 20 close · updated each morning
Downtrend
The stock is 5% below its 20 day and 17% below its 50 day average. It is 79% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 43). The nearest support is the Pivot S1 at $0.71, and the nearest resistance the Pivot at $0.77.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 10.4%/day
Key levels
$2.7352 week high+254.5%
$1.37200 day average+77.9%
$1.11100 day average+44.2%
$0.9050 day average+16.9%
$0.82Pivot R1+6.5%
$0.8120 day average+5.2%
$0.80Swing high (Oct 28)+3.9%
$0.77Pivot+0.0%
$0.77Last close
$0.71Pivot S1−7.8%
$0.70Swing low (Oct 26)−9.1%
$0.6952 week low−10.4%
Indicators
RSI (14)
42.87
Middle of its range
Neutral
MACD
-0.03
Below its signal line
Bearish
Stochastic
12.8
Near the bottom of its range
Oversold
ADX (14)
19.9
No clear trend
Williams %R
-83.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-40.6
Oversold below −100, overbought above 100
Neutral
Rate of change
−17.0%
Change over 10 sessions
Bearish
ATR (14)
$0.08
Typical daily range, 10.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 24.7%/day
Key levels
$2.7352 week high+254.5%
$1.37200 day average+77.9%
$1.11100 day average+44.2%
$0.9050 day average+16.9%
$0.82Pivot R1+6.5%
$0.8120 day average+5.2%
$0.80Swing high (Oct 28)+3.9%
$0.77Pivot+0.0%
$0.77Last close
$0.71Pivot S1−7.8%
$0.70Swing low (Oct 26)−9.1%
$0.6952 week low−10.4%
Indicators
RSI (14)
36.84
Weak, oversold below 30
Neutral
MACD
-0.18
Below its signal line
Bearish
Stochastic
18.7
Near the bottom of its range
Oversold
ADX (14)
18.9
No clear trend
Williams %R
-90.4
Oversold below −80, overbought above −20
Oversold
CCI (20)
-107.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−24.7%
Change over 10 sessions
Bearish
ATR (14)
$0.19
Typical daily range, 24.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for OCGN
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how OCGN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow OCGN usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for OCGNHow many large options trades hit OCGN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in OCGN in the last 90 days.
From SEC Form 4 filings by OCGN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OCGN is in one of them and how their past OCGN trades turned out.
From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data
About Ocugen
Ocugen is a company based in Malvern, Pennsylvania, that develops gene therapies for eye diseases. Its work centers on modifier gene therapies intended to treat inherited retinal diseases such as retinitis pigmentosa and Stargardt disease, as well as geographic atrophy, an advanced form of macular degeneration. The candidates are designed to be given as a single injection beneath the retina, with the aim of slowing vision loss in patients. The therapies are still in clinical development and are not yet approved for sale.